PCVX
Vaxcyte Inc
73.80$
+30.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.9% | +48.5% | -0.2% | +70.5% | -1.4% | -3.8% | -2.2% | -4.0% | -4.0% | +9.9% | -6.3% | |
| – | -15.4% | +38.4% | -2.3% | +49.4% | -19.2% | -4.0% | 0.0% | +3.0% | -7.9% | +11.4% | -14.4% | |
| – | -27.1% | +53.9% | -15.2% | +102.5% | -63.1% | -10.6% | -11.6% | -8.4% | -38.1% | +49.9% | -29.8% | |
| – | -14.7% | +37.6% | -2.3% | +50.1% | -19.9% | -4.3% | -0.6% | +3.0% | -8.8% | +11.3% | -14.4% | |
| – | +89.8% | -97.2% | +17,784.0% | -0.1% | +15.6% | – | – | +300.0% | +11,540.0% | – | – | |
| – | – | – | -176.5% | – | – | – | – | – | – | – | – | |
| – | +79.4% | -35.9% | -5.8% | +40.5% | +44.6% | -13.3% | +31.4% | +19.1% | +29.3% | -2.3% | +7.9% | |
| – | +69.9% | -40.1% | -4.9% | +49.4% | +13.2% | -30.8% | +59.3% | +29.5% | +2.9% | +17.7% | +12.1% | |
| – | +18.0% | +1.3% | +1.3% | +32.1% | -38.9% | +4.0% | +2.8% | -8.4% | +6.1% | -0.6% | +7.0% | |
| – | -7.1% | +48.9% | -51.8% | +74.1% | +165.9% | -57.7% | +53.1% | +55.9% | +44.8% | -11.1% | +60.0% | |
| – | -11.6% | +59.9% | +0.1% | +72.1% | -3.3% | -3.2% | -4.0% | -5.8% | -7.2% | +11.6% | -7.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.7% | +7.0% | +5.0% | +5.5% | -0.7% | +10.5% | +0.3% | +0.1% | -0.1% | +2.5% | +3.6% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.